Herein, we more than doubled the size of our population and still observed the same performance, with SS detecting KRAS mutations in 51% of tumor samples (n = 45) and ARMS–HRMA detecting mutations in 77% of tumor samples (n = 68). This evidence concerns the gene KRAS and neoplasm.